Related Experiment Video
Updated: Jan 6, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Investigate the potential inhibitors of sphingosine kinase 1 (SphK1) with molecular dynamics and artificial
Yahui Zhang1, Yiru Wang1, Junfeng Wan1
1College of Mathematics and Physics, Shanghai University of Electric Power, Shanghai, 200090, China.
Context:
Sphingosine kinase 1 (SphK1) is a sphingosine kinase that can catalyze the phosphorylation of sphingosine to generate sphingosine-1-phosphate. The J-type channel of SPHK1 plays an important role in processes such as cell signaling. Therefore, this study aims to investigate the interaction mechanism between Epidanshenspiroketallactone, PF-543, and SPHK1 in the J-type channel, and to design new small molecules using AI Drug Design (AIDD). Molecular dynamics (MD) simulations reveal that hydrophobic interactions and π-π stacking are of critical significance in stabilizing the J-channel conformation of Sphk1. With MD and AIDD methods, our research provides a novel potential approach for the exploration and design of SphK1 inhibitors.
Methods:
The binding mechanism of Epidanshenspiroketallactone and PF-543 with SphK1 was predicted by the molecular dynamics (MD) method using Gromacs-2022-2. Molecular docking was carried out with MolAICal, and the structures were visualized with the Pymol software. The MD simulation force field was selected as the AMBER99SB force field, the temperature was set at 310 K, and the total MD simulation time was 7.2 μs. A recurrent neural network-long short-term memory (RNN-LSTM) machine model was employed for the design of novel inhibitors.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Discovery: Overview

